Molecules

PSMA-I&T

Target PSMAClass Small molecule (urea, DOTAGA chelator)Other names zadavotide guraxetan

26ongoing trials
4radiolabelled forms
0approved products
247publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C63H92IN11O23
Molar mass (g/mol)
1,498.4
Exact mass (Da)
1,497.5412
XLogP
-7.7
H-bond donors
16
H-bond acceptors
27
Rotatable bonds
45
Heavy atoms
98
InChIKey
HPLNQICCRXHOIA-CIYKLJAQSA-N
PubChem record
CID 156596528 ↗
IUPAC name
(2S)-2-[[(1S)-1-carboxy-5-[[8-[[(5R)-5-carboxy-5-[[(2R)-2-[[(2R)-2-[[(4R)-4-carboxy-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]butanoyl]amino]-3-(4-hydroxy-3-iodophenyl)propanoyl]amino]-3-phenylpropanoyl]amino]pentyl]amino]-8-oxooctanoyl]amino]pentyl]carbamoylamino]pentanedioic acid
SMILES
C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)O)[C@H](CCC(=O)N[C@H](CC2=CC(=C(C=C2)O)I)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@H](CCCCNC(=O)CCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)CC(=O)O

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁷⁷Lu]Lu-PSMA-I&T Syntheses and QC ↗Therapy1,672.318Phase 3—
[²²⁵Ac]Ac-PSMA-I&T Syntheses and QC ↗Therapy—7Phase 3—
[¹⁶¹Tb]Tb-PSMA-I&T Syntheses and QC ↗Therapy—4Phase 2—
[⁶⁸Ga]Ga-PSMA-I&T Syntheses and QC ↗Imaging—0——

Ongoing trials · 26Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
VECTRA-01 · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT07611110 · Prostate – mCRPCPhase 3RecruitingAstraZeneca24
SPLASH · [177Lu]Lu-PSMA-I&T (PNT2002/zadavotide)NCT04647526 · Prostate – mCRPCPhase 3Active, not recruitingPOINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company6
[177Lu]PSMA-I&TNCT05204927 · Prostate – mCRPCPhase 3Active, not recruitingCurium US LLC4
[177Lu]PSMA-I&T2022-500570-33-00 · Prostate – otherPhase 3RecruitingRegion Västerbotten, Umea University1
PROSPECTOR · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT07590934 · Prostate – otherPhase 2RecruitingAstraZeneca7
AlphaBreak · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT06402331 · Prostate – mCRPCPhase 2Active, not recruitingFusion Pharmaceuticals Inc.1
LUNAR · [177Lu]Lu-PSMA-I&T (PNT2002/zadavotide)NCT05496959 · Prostate – localised / recurrencePhase 2Active, not recruitingJonsson Comprehensive Cancer Center1
LUST · [177Lu]PSMA-I&TNCT05893381 · Prostate – localised / recurrencePhase 2RecruitingIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1
PRODIGY-1 · [177Lu]PSMA-I&TNCT05896371 · Prostate – otherPhase 2Not yet recruitingCHU de Quebec-Universite Laval0
TATCIST · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT05219500 · Prostate – mCRPCPhase 2Active, not recruitingFusion Pharmaceuticals Inc.1
[225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT06909825 · Prostate – mCRPCPhase 2Active, not recruitingFusion Pharmaceuticals Inc.1
TeLuNa · [161Tb]/[177Lu]PSMA-I&TNCT07441837 · Prostate – mCRPCPhase 2Not yet recruitingAnkara University1
LUBASKET · [177Lu]PSMA-I&TNCT05867615 · Solid tumors (multiple indications)Phase 2Active, not recruitingIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1
[177Lu]PSMA-I&T2026-527110-23-00 · Prostate – mCRPCPhase 2Not yet recruitingRegion Uppsala1
[177Lu]PSMA-I&TNCT06220188 · Prostate – localised / recurrencePhase 2RecruitingMedical University of Vienna1
AlphaBet · [177Lu]PSMA-I&TNCT05383079 · Prostate – mCRPCPhase 2Active, not recruitingPeter MacCallum Cancer Centre, Australia1
[177Lu]PSMA-I&T2023-504696-24-00 · Brain (glioma, medulloblastoma…)Phase 2Not yet recruitingErasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)2
VIOLET · [161Tb]PSMA-I&TNCT05521412 · Prostate – mCRPCPhase 2RecruitingPeter MacCallum Cancer Centre, Australia1
[177Lu]PSMA-I&TNCT06259123 · Prostate – localised / recurrencePhase 2RecruitingMedical University of Vienna1
[177Lu]PSMA-I&T2026-526519-12-00 · Prostate – mCRPCPhase 2Not yet recruitingUniversitetssykehuset Nord-Norge HF1
PROGNOSTICS · [161Tb]/[177Lu]PSMA-I&TNCT06343038 · Prostate – mCRPCPhase 1RecruitingUniversity Hospital, Basel, Switzerland1
LumOnate · [177Lu]PSMA-I&TNCT07090369 · Prostate – mCRPCPhase 1Not yet recruitingPeter MacCallum Cancer Centre, Australia1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT04886986 · Prostate – mCRPCPhase 1RecruitingWeill Medical College of Cornell University1
[225Ac]PSMA-I&T2024-513729-22-01 · Prostate – otherPhase 1RecruitingErasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)1
[177Lu]PSMA-I&TNCT07316686 · Prostate – mCRPCPhase 1RecruitingInstituto do Cancer do Estado de São Paulo1
[161Tb]PSMA-I&TNCT07621692 · Prostate – mCRPCPhase 1RecruitingNational Taiwan University Hospital1

Published results · 2

2026-10LUNAR (extended follow-up) · positiveTwo cycles of ¹⁷⁷Lu-PSMA before stereotactic radiotherapy of hormone-sensitive oligorecurrence: progression-free survival of 17.6 vs 7.4 months (HR 0.38) and delayed need for hormone therapy, with 32 months of follow-up.Eur Urol ↗
2026-06Lu-PSMA + capecitabine · earlyNo limiting toxicity up to 1,000 mg/m² of capecitabine (12 patients); PSA50 of 50%. A signal to confirm in a larger cohort.Eur J Nucl Med Mol Imaging ↗

PublicationsAll publications in PubMed ↗

247 publications in PubMed for the query below; the most recent:

"PSMA I&T"[tiab] OR "PSMA-I&T"[tiab] OR zadavotide[tiab]

  1. [(177)Lu] Lu-PSMA-I&T for prostate cancer radioligand therapy: A radiopharmacy's journey from synthesis to cost-effectiveness Appl Radiat Isot, 2026
  2. Multimodal Visual Question Answering System for Survival Prognosis in PSMA-Targeted Radiopharmaceutical Therapy J Nucl Med, 2026
  3. Preclinical Evaluation on the Radiohybrid Tandem [(18)F]La- and [(225)Ac]Ac-rhPSMA-10.1 for Targeted α-Therapy of Prostate Cancer J Nucl Med, 2026
  4. Outcome Prediction After [(177)Lu]Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [(68)Ga]Ga-PSMA-11 PET-Based Model with [(18)F]F-Flotufolastat J Nucl Med, 2026
  5. Rapid Lymphatic Clearance After Subcutaneous Extravasation of 177 Lu-PSMA-I&T Radioligand Therapy Clin Nucl Med, 2026
  6. Gallium-68 (68Ga)-Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Initial Staging of High-Risk Prostatic Adenocarcinoma: Reclassification to Oligometastatic Disease and Change in Treatment Intent Cureus, 2026
  7. Influence of increased injected activities up 9.0 GBq [(177)Lu]Lu-PSMA-I&T on absorbed doses to lesions and kidneys EJNMMI Phys, 2026
  8. Overall Survival with [(177)Lu]Lu-PSMA-617 Versus [(177)Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis J Nucl Med, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

PSMA-I&T. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/psma-it/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.